Friday, May 15, 2026

In Detail Full day, Friday, May 15, 2026, Timezone: America/Chicago

Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape

oncodaily - Bristol Myers Squibb (NYSE: BMY) and Jiangsu Hengrui Pharma (600276.SH; 01276.HK) on Tuesday unveiled one of the largest cross-border biopharma collaborations of the year: a global strategic alliance encompassing 13 […]

AI Summary: Bristol Myers Squibb and Hengrui Pharma announced a sweeping strategic alliance covering multiple oncology assets, with potential payments and milestones that could reach roughly $15.2 billion. The deal bundles discovery, development and commercialization rights, reshaping China‑out‑licensing dynamics and signaling continued consolidation and collaboration in global cancer drug development.

Supreme Court preserves access to abortion pill by mail

Sydney Halleman / healthcaredive - The ruling maintains access to mifepristone while litigation continues. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits.

AI Summary: The Supreme Court intervened to maintain access to mifepristone, temporarily restoring telehealth prescribing and preserving mail distribution while litigation proceeds. The decision keeps the pill available nationwide, blocking lower-court restrictions that would have sharply limited remote access and complicated routine clinical care for patients and providers.